DIGOXIN tablet labels and packages: Difference between revisions

Revision as of 05:39, 13 March 2014

Digoxin
DIGOXIN injection^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
DIGOXIN tablet^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: :Abdurahman Khalil, M.D. [2]

For patient information about Digoxin, click here.

PRINCIPAL DISPLAY PANEL

NDC 0143-1240-01 Digoxin Tablets, USP 125 mcg (0.125 mg) Rx Only 100 Tablets

PRINCIPAL DISPLAY PANEL

NDC 0143-1241-01 Digoxin Tablets, USP 250 mcg (0.25 mg) Rx Only 100 Tablets

@@ Line 4: / Line 4: @@
 '''''For patient information about Digoxin, click [[Digoxin (patient information)|here]].'''''
+==Labels and Packages==
 '''PRINCIPAL DISPLAY PANEL